v3.26.3
Segment Disclosures (Tables)
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
Schedule of Selected Financial Information
The following table presents selected financial information with respect to the Company's single operating segment for the three and nine months ended September 30, 2026 and 2025:
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues
Commercial and development revenue$1,604 $1,508 $3,820 $1,508 
License and collaboration revenue— 158 24 210 
Total revenues1,604 1,666 3,844 1,718 
Less:
Cost of sales2,669 1,577 9,556 1,577 
Research and development
Clinical and manufacturing31,940 23,381 122,012 72,818 
Other research and development(1)
7,281 4,503 15,596 13,865 
Total research and development39,221 27,884 137,608 86,683 
General and administrative22,963 23,334 72,719 55,532 
Total costs and operating expenses64,853 52,795 219,883 143,792 
Loss from operations(63,249)(51,129)(216,039)(142,074)
Other income, net6,358 7,321 19,890 22,388 
Net loss$(56,891)$(43,808)$(196,149)$(119,686)
(1)Other research and development consists of indirect costs incurred for the benefit of the research and development efforts, including certain personnel, supply chain, quality assurance, and regulatory affairs.